Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems, Inc. focuses on revolutionizing blood collection through innovative, minimally invasive technology that simplifies the process for both patients and healthcare providers. Founded in 2008 in Medford, US, Seventh Sense Biosystems, Inc. specializes in developing advanced blood collection solutions.

The company has not undergone any significant changes in business operations. The latest funding round was a Series B totaling USD 21. 000 mn, led by Flagship Pioneering, with participation from Newpath Partners, bringing the total amount raised to USD 21. 000 mn and a current valuation of USD 54.

515 mn. Seventh Sense Biosystems, Inc. offers innovative blood collection solutions through its proprietary TAP® devices, specifically the TAP® Micro and TAP® Micro Select. Utilizing HALO™ technology with bladeless microneedles, these devices enable virtually painless blood collection at home or in decentralized clinical settings, addressing common challenges in traditional phlebotomy.

The primary users are patients requiring blood tests, especially in pediatric and clinical trial contexts, with applications in hospitals and wellness testing across the United States and Europe. The company generates revenue through direct sales of its TAP® devices and associated services to healthcare providers, hospitals, and research institutions. Operating on a B2B model, it provides high-quality, remote blood collection solutions essential for decentralized clinical trials and routine testing. Each transaction involves the purchase of TAP® devices, with pricing and subscription models tailored through partnerships with healthcare organizations.

In September 2021, Seventh Sense Biosystems, Inc. raised USD 21. 000 mn in venture funding to accelerate future growth and support new product launches. The company plans to introduce additional products designed to enhance blood collection efficiency and comfort, while targeting expansion into new geographic markets in the coming years.